APH1A

Across TCGA pan-cancer cohorts, APH1A Mutation is linked to patient survival in 2 of 34 cancer types, making it a survival-associated APH1A data layer compared with 28 for mass-spec protein and 4 for mass-spec protein.

The strongest signal is observed in ovarian serous cystadenocarcinoma (OV), where higher APH1A Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated APH1A expression acts as an unfavorable survival marker.

OV and UCEC are the cancer types where APH1A Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
OV	DFS	Median	II,III,IV	0.174	0.541	.009	18	view →
UCEC	OS	Median	IV	0.231	0.592	.036	6	view →

Pink = unfavorable, green = favorable. Showing the 2 strongest of 2 lineages.

APH1A–OV (DFS)

Open the OV breakdown →